News and Announcements
FDA Allows Prescient IND for Leukemia Phase Ib & II Trials
- Published January 08, 2016 11:21AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th January 2016, ASX Announcement
Highlights:
- PTX has four FDA approved INDs demonstrating the strength of its cancer treatment assets
- Follows Phase I study that demonstrated 17 out of 32 patients achieved disease stabilization. These were patients with advanced leukemia with few remaining treatment options
Clinical stage oncology company Prescient Therapeutics Ltd (PTX) has secured US Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application for the forthcoming Phase Ib and Phase II clinical trial and program in acute myeloid leukemia (AML).
The study will combine PTX’s lead drug candidate, the novel AKT inhibitor PTX-200, together with the chemotherapeutic agent cytarabine, in refractory or relapsed patients with AML.
The Phase Ib and Phase II studies will be lead by hematologist Professor Jeffrey Lancet at the Moffitt Cancer Center and Research Institute (Moffit) in Tampa, FL USA.
To read the full announcement, please click here.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
